PTGDR2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL134982	1.00	20/20
SCHEMBL135143	1.00	20/20
SCHEMBL136287	1.00	20/20
SCHEMBL136303	1.00	20/20
SCHEMBL136437	1.00	20/20
SCHEMBL137033	1.00	20/20
SCHEMBL137229	1.00	20/20
SCHEMBL137334	1.00	20/20
SCHEMBL137752	1.00	20/20
SCHEMBL137822	1.00	20/20
SCHEMBL137951	1.00	20/20
SCHEMBL138446	1.00	20/20
Am-211 (SCHEMBL138450)	1.00	20/20
SCHEMBL136971	0.93	20/20
SCHEMBL137393	0.88	20/20
SCHEMBL135006	0.86	20/20
SCHEMBL136279	0.86	20/20
SCHEMBL137890	0.86	20/20
SCHEMBL137380	0.85	20/20
SCHEMBL134978	0.85	20/20

Clinical trials — most relevant to PTGDR2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite	PHASE2/PHASE3	WITHDRAWN
European Celecoxib Trial in Primary Breast Cancer	PHASE3	COMPLETED
Selective COX-II Inhibitor as a Palliative Therapy in Patients With R1 or R2 Resection for Disseminated Stomach Cancer - A Multi-Centre Prospective Randomized Controlled Trial	PHASE3	UNKNOWN
Aspirin and Renal Disease Progression in Patients With Type 2 Diabetes	PHASE3	UNKNOWN
Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial	PHASE3	UNKNOWN
Addition of Aspirin to Standard of Care in Oral Cancer	PHASE2/PHASE3	COMPLETED
Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs	PHASE3	COMPLETED
Changes in Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors	PHASE1/PHASE2	COMPLETED
Effect of OC459 on the Response to Rhinovirus Challenge in Asthma	PHASE2	COMPLETED
Adjunctive Celecoxib in Childhood-onset OCD Study	PHASE2	UNKNOWN
Assessment of Therapeutic Effect of Rectal Vs. Intravenous Paracetamol in The Treatment of Patent Ductus Arteriosus (PDA) in Neonates	PHASE1/PHASE2	UNKNOWN
Ibuprofen Versus Acetaminophen for Treatment of Mild Traumatic Brain Injury	PHASE2	WITHDRAWN
Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor	PHASE2	COMPLETED
DHA For The Treatment of Pediatric Concussion Related to Sports Injury	PHASE1	COMPLETED
Study About Patients Using Copper Intrauterine Device	nan	COMPLETED
Clinical Research of the Prognostic Influence of NSAIDS's Anti-inflammatory Effect on Senior Patients With Hip Fracture	nan	UNKNOWN
Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B	nan	COMPLETED
Lipidomics Screening of Anti-inflammatory Drugs and Drug Candidates in Vitro - Part A	nan	ACTIVE_NOT_RECRUITING
PGE2/IL-22 Pathway in Various Forms of Eczema	nan	COMPLETED
Relation Between Prostaglandin E2 Metabolite Levels and the Development of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Neonates	nan	RECRUITING
Maresin-1 and Resolvin-D1 Levels and Disease Activity in Ulcerative Colitis	nan	COMPLETED
The Efficacy of Two Types of Acupuncture on Autonomic Nervous Activity and Quality of Life in Women With Dysmenorrhea.	nan	UNKNOWN
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish)	nan	UNKNOWN
Forced Oscillometry in Infants With Bronchopulmonary Dysplasia	nan	RECRUITING
Characterization of the Inhibitory Effects of Fevipiprant (QAW039) on Activation of Eosinophils and ILC2 Cells by Prostaglandin D2 Metabolites	nan	COMPLETED
PET Imaging of DHA Metabolism	nan	COMPLETED
Prostaglandin and Cannabinoid Receptors in EoE	nan	COMPLETED
Association and Mechanism Between Cyclooxygenase-2 and Interleukin-6 in Gastric Cancer	nan	UNKNOWN
Peri-implantitis and MMP-8	nan	COMPLETED
Molecular Effects of Short-Term Celecoxib Treatment on Head and Neck Squamous Cell Carcinoma	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PTGDR2 binder may also engage these)

Protein	Name	Similarity
Q9Z2J6	—	0.997	Q9Z2J6 →
Q6XKD3	—	0.994	Q6XKD3 →
RXFP4	Relaxin-3 receptor 2	0.981	landscape →
Q8NGA4	—	0.981	Q8NGA4 →
Q8BW93	—	0.978	Q8BW93 →
C5AR2	C5a anaphylatoxin chemotactic receptor 2	0.975	landscape →
P0C5I1	—	0.974	P0C5I1 →
O00155	—	0.972	O00155 →
Q695P6	—	0.971	Q695P6 →
Q920E0	—	0.971	Q920E0 →
Q9TUE1	—	0.970	Q9TUE1 →
O70129	—	0.970	O70129 →
P79240	—	0.968	P79240 →
O75388	—	0.968	O75388 →
LPAR5	Lysophosphatidic acid receptor 5	0.968	landscape →
P2RY11	P2Y purinoceptor 11	0.968	landscape →
O09027	—	0.967	O09027 →
P79175	—	0.966	P79175 →
C5AR1	C5a anaphylatoxin chemotactic receptor 1	0.966	landscape →
P31392	—	0.965	P31392 →
P43142	—	0.964	P43142 →
Q7TQP4	—	0.964	Q7TQP4 →
Q3ZC80	—	0.964	Q3ZC80 →
O88634	—	0.964	O88634 →
Q9JL21	—	0.964	Q9JL21 →
O00590	—	0.963	O00590 →
Q76JU9	—	0.963	Q76JU9 →
P30993	—	0.963	P30993 →
GALR2	Galanin receptor type 2	0.962	landscape →
O00270	—	0.961	O00270 →